

Breast Cancer Pathways: Adjuvant

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op

ECOG Performance Status: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (Select all that apply)

Estrogen Receptor (ER): Negative Positive

OncotypeDx: Low* Intermediate

Progesterone Receptor (PR): Negative Positive

High Not Done/Reported

HER2 status by FISH/CISH: Negative Positive Equivocal

Include ovarian suppression (pre-menopause only):

or by IHC: 0 1+ 2+ 3+

Yes No Unknown

Adjuvant Therapy | HER2 Negative*

ddAC → weekly T: dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel

TC: docetaxel (Taxotere) and cyclophosphamide

Adjuvant Therapy | HER2 Positive

AC → TH: doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel and trastuzumab (Herceptin)†

TCH: docetaxel (Taxotere), carboplatin, and trastuzumab (Herceptin)†

TH: paclitaxel and trastuzumab (Herceptin)† (**Pathway for stage I, HER2 positive breast cancer only**)

Adjuvant Therapy | HER2 Negative | Hormone Receptor (ER/PR) Negative | Residual Disease following Neoadjuvant Therapy

Capecitabine (Xeloda)

*Adjuvant chemotherapy pathways do NOT apply to individuals with hormone-receptor positive, lymph node negative, OncotypeDX™ LOW risk score

†Administration of trastuzumab (Herceptin) is limited to 17 cycles (approximately 1 year)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 02/20/2018 | Effective date: 04/30/2018

Appropriate.Safe.Affordable

© 2018 AIM Specialty Health
9001-0418b